Evolus, Inc. (LON: 0K16)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 692.84M |
| Revenue (ttm) | 185.28M |
| Net Income (ttm) | -41.38M |
| Shares Out | n/a |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,432 |
| Average Volume | 4,009 |
| Open | 13.68 |
| Previous Close | 13.67 |
| Day's Range | 13.68 - 14.36 |
| 52-Week Range | 7.12 - 15.38 |
| Beta | n/a |
| RSI | 67.50 |
| Earnings Date | Mar 10, 2025 |
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and... [Read more]
Financial Performance
In 2023, Evolus's revenue was $202.09 million, an increase of 35.98% compared to the previous year's $148.62 million. Losses were -$61.69 million, -17.10% less than in 2022.
Financial numbers in USD Financial StatementsNews
Evolus Inc (EOLS) Shares Gap Down to $10.33 on Jan 8
Evolus Inc (EOLS) Shares Gap Down to $10.33 on Jan 8
Evolus Inc (EOLS) Trading Down 3.61% on Dec 27
Evolus Inc (EOLS) Trading Down 3.61% on Dec 27
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in Novemb...
Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript
Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript
Evolus Reports Third Quarter 2024 Results
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results f...
Evolus to Participate in Stifel 2024 Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Dev...
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpas...
Evolus to Report Third Quarter Financial Results on November 6, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasda...
Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Nareg Sagherian - Vice President and Head of Global Investor Relations and Corporate Communic...
Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival
Evolus , an anti-wrinkle injection maker, reported its first-ever quarterly profit on an adjusted basis on Wednesday, driven by strong sales of its Botox rival Jeuveau.
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results f...
Evolus to Hold Investor Day on September 12, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host ...
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of N...
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sandra Beaver...
Evolus to Report Second Quarter Financial Results on July 31, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus Announces Appointment of Albert G. White III to Board of Directors
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of...
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submit...
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A...
Evolus: Chiseling Away At The Aesthetic Market
Evolus is a facial beauty company that specializes in aesthetic neurotoxins, with its flagship product being Jeuveau. The company is expanding its product portfolio by adding dermal fillers through ex...
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline r...
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its participation ...
Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Fin...
Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head, Global IR and Corporate Communications David Moatazedi - Preside...